[painkiller]

Check out Normast , a new painkiller based on one of our own molecules, palmitoylethanolamide. Evaluated in many clinical trials and used in Europe in over 800.000 patients.

[mrsD]

This product is not sold in US...

Lipids Health Dis. 2010 May 14;9:47.
Possible Anandamide and Palmitoylethanolamide involvement in human stroke.

Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, Pizzolato G, Di Marzo V.

Department of Medical, Technological and Translational Sciences, Neurology Unit, University of Trieste, Strada di Fiume 447, 34100 Trieste (TS), Italy. marcello.naccarato@katamail.com
Abstract

BACKGROUND: Endocannabinoids (eCBs) are ubiquitous lipid mediators that act on specific (CB1, CB2) and non-specific (TRPV1, PPAR) receptors. Despite many experimental animal studies proved eCB involvement in the pathogenesis of stroke, such evidence is still lacking in human patients. Our aim was to determine eCB peripheral levels in acute stroke patients and evaluate their relationship with clinical disability and stroke volume.

METHODS: A cohort of ten patients with a first acute (within six hours since symptoms onset) ischemic stroke and a group of eight age- and sex-matched normal subjects were included. Groups were also matched for metabolic profile. All subjects underwent a blood sample collection for anandamide (AEA), 2-arachidonoylglycerol (2-AG) and palmitoylethanolamide (PEA) measurement; blood sampling was repeated in patients on admission (T0), at 6 (T1) and 18 hours (T2) thereafter. Patients neurological impairment was assessed using NIHSS and Fugl-Meyer Scale arm subitem (FMSa); stroke volume was determined on 48 h follow-up brain CT scans. Blood samples were analyzed by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry.

RESULTS: 1)T0 AEA levels were significantly higher in stroke patients compared to controls. 2)A significant inverse correlation between T0 AEA levels and FMSa score was found. Moreover a positive correlation between T0 AEA levels and stroke volume were found in stroke patients. T0 PEA levels in stroke patients were not significantly different from the control group, but showed a significant correlation with the NIHSS scores. T0 2-AG levels were lower in stroke patients compared to controls, but such difference did not reach the significance threshold.

CONCLUSIONS: This is the first demonstration of elevated peripheral AEA levels in acute stroke patients. In agreement with previous murine studies, we found a significant relationship between AEA or PEA levels and neurological involvement, such that the greater the neurological impairment, the higher were these levels.

Also elevated in obese diabetic patients:
http://www.ncbi.nlm.nih.gov/pubmed/20426869

At this time taking extra of PEA does not seem wise, until its actions in human disease states are explained further.

There is also a paper on MS patients.

This is very new:

Biochimie. 2010 Jun;92(6):724-7. Epub 2010 Jan 21.
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities.

Petrosino S, Iuvone T, Di Marzo V.

Institute of Biomolecular Chemistry - CNR, Endocannabinoid Research Group, Via Campi Flegrei 34, 80078 Pozzuoli (Naples), Italy.
Abstract

Although its presence in mammalian tissues has been known since the 1960s, N-palmitoyl-ethanolamine (PEA) has emerged only recently among other bioactive N-acylethanolamines as an important local pro-homeostatic mediator which, due to its chemical stability, can be also administered exogenously as the active principle of current anti-inflammatory and analgesic preparations (e.g. Normast, Pelvilen). Much progress has been made towards the understanding of the mechanisms regulating both the tissue levels of PEA under physiological and pathological conditions, and its pharmacological actions. Here we review these new developments in PEA biochemistry and pharmacology, and discuss novel potential indications for the therapeutic use of this compound and of synthetic tools that selectively retard its catabolism, such as the inhibitors of the recently cloned N-acylethanolamine-hydrolyzing acid amidase.
Copyright 2010 Elsevier Masson SAS. All rights reserved.

PMID: 20096327 [PubMed - indexed for MEDLINE]

I'd like to see more studies and safety information before trying this or recommending it.
So far I only see one supplier in Italy.

[Lemnoc]

Originally Posted by painkiller

Check out Normast , a new painkiller based on one of our own molecules, palmitoylethanolamide. Evaluated in many clinical trials and used in Europe in over 800.000 patients.

I do not think this is legal in the U.S.